{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:54:41Z","timestamp":1785704081496,"version":"3.56.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.06.010","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:10:21Z","timestamp":1782079821000},"page":"e987-e995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"26","author":[{"given":"Carlotta","family":"Pazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2026.06.010_bib0001","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2026.06.010_bib0002","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2026.06.010_bib0003","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.clml.2026.06.010_bib0004","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2026.06.010_bib0006","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2026.06.010_bib0007","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.06.010_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.06.010_bib0009","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/ijms24055018","article-title":"Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Zavras","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.clml.2026.06.010_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.06.010_bib0011","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.06.010_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2026.06.010_bib0013","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.06.010_bib0014","doi-asserted-by":"crossref","first-page":"e862","DOI":"10.1016\/S2352-3026(24)00251-5","article-title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","volume":"11","author":"Komrokji","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.clml.2026.06.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104931","article-title":"A machine learning model of response to hypomethylating agents in myelodysplastic syndromes","volume":"25","author":"Radakovich","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cancers16010065","article-title":"Integrating AI and ML in Myelodysplastic syndrome diagnosis: state-of-the-art and future prospects","volume":"16","author":"Elshoeibi","year":"2023","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.010_bib0017","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1182\/blood-2024-211667","article-title":"A self-supervised machine learning model can differentiate MDS from clinical mimics based on bone marrow biopsy features","volume":"144","author":"Jafarzadeh","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.06.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.clml.2026.06.010_bib0019","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2026.06.010_bib0020","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.06.010_bib0021","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1007\/s00277-025-06570-0","article-title":"Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice","volume":"104","author":"Schulz","year":"2025","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.010_bib0022","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2023-187053","article-title":"Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (Pts) with myelodysplastic syndromes\/neoplasms (MDS) with missing molecular data","volume":"142","author":"Kewan","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.06.010_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091693","article-title":"Genomic characterization of partial tandem duplication involving the KMT2A gene in adult acute myeloid leukemia","volume":"16","author":"Seto","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.06.010_bib0024","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2024-200405","article-title":"Detection of KMT2A partial tandem duplication in myeloid samples by Pacbio\u00ae long read sequencing","volume":"144","author":"Todd","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.06.010_bib0025","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2026.06.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500124","article-title":"Prognostic score for myelodysplastic syndromes based on molecular evolution","volume":"5","author":"Civettini","year":"2026","journal-title":"NEJM Evid"},{"issue":"16","key":"10.1016\/j.clml.2026.06.010_bib0027","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/bloodadvances.2023010098","article-title":"Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes","volume":"7","author":"Schulz","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2026.06.010_bib0028","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/bloodadvances.2024014865","article-title":"Advancing drug development in myelodysplastic syndromes","volume":"9","author":"Mina","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.06.010_sbref0029","series-title":"Advancing drug development in myelodysplastic syndromes","year":"2023"},{"issue":"18","key":"10.1016\/j.clml.2026.06.010_bib0030","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.2024025131","article-title":"Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT","volume":"145","author":"Gurnari","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.06.010_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082248","article-title":"What\u2019s next after hypomethylating agents failure in myeloid neoplasms? A rational approach","volume":"15","author":"Awada","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44228-022-00024-4","article-title":"How I manage transplant ineligible patients with myelodysplastic neoplasms","volume":"5","author":"Gurnari","year":"2022","journal-title":"Clin Hematol Int"},{"issue":"18","key":"10.1016\/j.clml.2026.06.010_bib0033","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2024025271","article-title":"How I treat higher-risk MDS","volume":"145","author":"Mina","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.06.010_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clml.2022.11.002","article-title":"Azacitidine monotherapy in patients with treatment-na\u00efve higher-risk myelodysplastic syndrome: a systematic literature review and meta-analysis","volume":"23","author":"Hasegawa","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.clml.2026.06.010_bib0035","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.010_bib0036","article-title":"The coming of age of preclinical models of MDS","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.010_bib0037","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41375-024-02181-2","article-title":"The evolution of preclinical models for myelodysplastic neoplasms","volume":"38","author":"Mina","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0038","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41419-025-07861-0","article-title":"Humanized mouse models in MDS","volume":"16","author":"Munteanu","year":"2025","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0039","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41467-018-08166-x","article-title":"A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/bloodadvances.2024013361","article-title":"Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment","volume":"9","author":"Ren","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2026.06.010_bib0041","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","article-title":"Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.clml.2026.06.010_bib0042","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2025029727","article-title":"The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials","volume":"147","author":"Stahl","year":"2026","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2026.06.010_bib0043","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2026.06.010_bib0044","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2026.06.010_bib0045","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2026.06.010_bib0046","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"issue":"31","key":"10.1016\/j.clml.2026.06.010_bib0047","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody Magrolimab combined with Azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.06.010_bib0048","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/bloodadvances.2025016229","article-title":"Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS","volume":"9","author":"DeZern","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.06.010_bib0049","doi-asserted-by":"crossref","unstructured":"Linder K, Lulla P Myelodysplastic syndrome and immunotherapy novel to next in-line treatments. Hum Vaccines Immunother. 17(8):2602-2616. doi:10.1080\/21645515.2021.1898307.","DOI":"10.1080\/21645515.2021.1898307"},{"key":"10.1016\/j.clml.2026.06.010_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102673","article-title":"Phase to phase: navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes","volume":"123","author":"Merz","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.clml.2026.06.010_bib0051","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.010_bib0052","unstructured":"Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS) | Dana-Farber Cancer Institute. Accessed: May 24, 2026. Available at: https:\/\/www.dana-farber.org\/newsroom\/news-releases\/2025\/phase-iii-verona-trial-results-show-potential-benefit-for-some-groups-with-myelodysplastic-syndrome-mds."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.010_bib0053","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-235","article-title":"Subgroup analyses from the randomized, phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes (HR MDS)","volume":"146","author":"Garcia-Manero","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.010_bib0054","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-5647","article-title":"A phase I\/II trial of azacitidine and venetoclax in previously untreated myelodysplastic syndromes","volume":"146","author":"Bouligny","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.010_bib0055","unstructured":"A phase II study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, alternating with Azacitidine and Venetoclax, in patients with higher-risk myelodysplastic\/myeloproliferative neoplasms or higher-risk myelodysplastic syndromes with excess blasts. UT MD Anderson. Accessed: May 25, 2026. Available at: https:\/\/www.mdanderson.org\/patients-family\/diagnosis-treatment\/clinical-trials\/clinical-trials-index\/clinical-trials-detail.html."},{"key":"10.1016\/j.clml.2026.06.010_bib0056","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-4905","article-title":"Dual BCL-xL and BCL-2 inhibition for advanced myeloid neoplasms: a phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine","author":"Chen","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.06.010_bib0057","unstructured":"Tan Y. A single-arm, prospective clinical study of venetoclax combined with Azacitidine followed by bridging transplantation in patients with high-risk myelodysplastic neoplasms with increased blasts 2 (MDS-IB2). clinicaltrials.gov; 2025. Accessed May 24, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07047183."},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0058","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","article-title":"Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study","volume":"14","author":"Zugasti","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.010_bib0059","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.06.010_bib0060","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cancers16030532","article-title":"Smart conditioning with venetoclax-enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies","volume":"16","author":"Schulz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.06.010_bib0061","unstructured":"Heinrich-Heine University, Duesseldorf. Phase-I,II trial to assess the safety and efficacy of venetoclax in addition to sequential conditioning with fludarabine \/amsacrine \/ara-C (FLAMSA) + treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML. clinicaltrials.gov; 2024. Accessed: May 25, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05807932."},{"issue":"3","key":"10.1016\/j.clml.2026.06.010_bib0062","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jha2.915","article-title":"Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies","volume":"5","author":"Parks","year":"2024","journal-title":"eJHaem"},{"issue":"4","key":"10.1016\/j.clml.2026.06.010_bib0063","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0609.2012.01830.x","article-title":"Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype","volume":"89","author":"Wudhikarn","year":"2012","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.010_bib0064","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/leu.2012.297","article-title":"Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"27","author":"van Gelder","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.06.010_bib0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41409-023-01931-7","article-title":"Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS","volume":"58","author":"Michel","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.clml.2026.06.010_bib0066","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.clml.2026.06.010_bib0067","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1158\/1078-0432.CCR-25-1005","article-title":"FDA approval summary: ivosidenib for treatment of adult patients with relapsed\/refractory myelodysplastic syndrome with an IDH1 mutation","volume":"31","author":"Woods","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.clml.2026.06.010_bib0068","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1182\/bloodadvances.2025016718","article-title":"Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome","volume":"9","author":"Cortes","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2026.06.010_bib0069","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molmed.2015.11.005","article-title":"Small molecule modulators of pre-mRNA splicing in cancer therapy","volume":"22","author":"Salton","year":"2016","journal-title":"Trends Mol Med"},{"issue":"23","key":"10.1016\/j.clml.2026.06.010_bib0071","doi-asserted-by":"crossref","first-page":"24246","DOI":"10.1074\/jbc.M314298200","article-title":"Manipulation of alternative splicing by a newly developed inhibitor of Clks","volume":"279","author":"Muraki","year":"2004","journal-title":"J Biol Chem"},{"issue":"7367","key":"10.1016\/j.clml.2026.06.010_bib0072","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2026.06.010_bib0073","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41467-016-0008-7","article-title":"CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor","volume":"8","author":"Funnell","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.clml.2026.06.010_bib0074","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240718","article-title":"Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors","volume":"15","author":"Murai","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.clml.2026.06.010_bib0075","unstructured":"BlossomHill Therapeutics. A phase 1\/1b open-label, dose escalation, first-in- Human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-Like Kinase (CLK) inhibitor, BH-30236, in adults with relapsed or refractory acute myelogenous leukemia (R\/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). clinicaltrials.gov; 2025. Accessed: June 1, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06501196."},{"issue":"10","key":"10.1016\/j.clml.2026.06.010_bib0076","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2026.06.010_bib0077","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3R\u03b1 in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.010_bib0078","doi-asserted-by":"crossref","unstructured":"Nguyen D Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML. In: ASH; 2024. Accessed: May 25, 2026. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper208684.html.","DOI":"10.1182\/blood-2024-208684"},{"issue":"6","key":"10.1016\/j.clml.2026.06.010_bib0079","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.06.010_bib0080","unstructured":"Inc A. Arcellx presents pre-clinical data for ACLX-002, a novel CD123-targeted universal CAR-T cell therapy for relapsed or refractory acute myeloid leukemia at the American Association for Cancer Research Annual Meeting. Accessed: May 28, 2026. Available at: https:\/\/www.prnewswire.com\/news-releases\/arcellx-presents-pre-clinical-data-for-aclx-002-a-novel-cd123-targeted-universal-car-t-cell-therapy-for-relapsed-or-refractory-acute-myeloid-leukemia-at-the-american-association-for-cancer-research-annual-meeting-301520948.html."},{"key":"10.1016\/j.clml.2026.06.010_bib0081","unstructured":"Phase I study of cell therapies for the treatment of patients with relapsed or refractory AML or high-risk MDS - NCI. 2016. Accessed: May 28, 2026. Available at: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2022-08124."},{"issue":"10","key":"10.1016\/j.clml.2026.06.010_bib0082","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1080\/10428194.2025.2514662","article-title":"Optimal timing of allogeneic hematopoietic stem cell transplant in MDS","volume":"66","author":"Rathje","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2026.06.010_bib0083","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V22.6.2025617","article-title":"VERONA and the future of high-risk myelodysplastic syndromes: a conversation with Dr. Jacqueline Garcia","volume":"22","author":"Brierley","year":"2025","journal-title":"Hematologist"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2026.06.010_bib0084","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2019-124437","article-title":"A phase 1b study evaluating the safety and efficacy of Venetoclax in combination with Azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.010_bib0085","unstructured":"M.D. Anderson Cancer Center. A phase I\/II study of venetoclax in combination with ASTX727 (Cedazuridine\/Decitabine) in treatment-na\u00efve high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). clinicaltrials.gov; 2026. Accessed: May 25, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04655755."},{"key":"10.1016\/j.clml.2026.06.010_bib0086","unstructured":"Oral azacitidine combined with venetoclax in previously untreated higher-risk myelodysplastic syndromes | clinical research trial listing. Accessed: May 25, 2026. Available at: https:\/\/www.centerwatch.com\/clinical-trials\/listings\/NCT05782127\/oral-azacitidine-combined-with-venetoclax-in-previously-untreated-higher-risk-myelodysplastic-syndromes\/oral-azacitidine-combined-with-venetoclax-in-previously-untreated-higher-risk-myelodysplastic-syndromes."},{"key":"10.1016\/j.clml.2026.06.010_bib0087","unstructured":"Place AE A phase I study of venetoclax in combination with cytotoxic chemotherapy, including Calaspargase Pegol, for children, adolescents and young adults with high-risk hematologic malignancies. clinicaltrials.gov; 2026. Accessed: May 25, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05292664."},{"key":"10.1016\/j.clml.2026.06.010_bib0088","unstructured":"Venetoclax Combined with intensive chemotherapy for the treatment of newly diagnosed acute myeloid leukemia or intermediate and higher risk myelodysplastic syndrome - NCI. 2016. Accessed May 25, 2026. Available at: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2022-05682."},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.010_bib0089","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6549","article-title":"A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older\/unfit pts with newly diagnosed (ND) or pts with relapsed\/refractory (R\/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS)","volume":"42","author":"Swaminathan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.010_bib0090","unstructured":"Garcia J A phase 1 study of Triplet therapy with navitoclax, venetoclax, and decitabine for high-risk myeloid malignancies. clinicaltrials.gov; 2026. Accessed: May 28, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05455294."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:23Z","timestamp":1785701963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001849"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}